Sign in
HBPCF Stock Price, Chart, Stats & News
Helix BioPharma Corp
Save
Helix BioPharma Corp (HBPCF) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
HBPCF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to interact with vascular epithelial growth factor receptor 2 (VEGFR2). Helix has established collaborative agreements to further its research.
Similar securities
Based on sector and market capitalization
Report issue